Omeros Corp. (OMER)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1285819 · fiscal year ends in Dec
Closing price $18.94 on 29 Oct 2026; 52-week range $6.28 to $21.05.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $1.4B
- Cash
- $2.0M
- Debt
- $73.3M
- Shares outstanding
- 72.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2020 | 31 Dec 2020 | $73.8M | -$156.9M | -$138.1M | -$2.41 | -$100.4M | 10-K filed 1 Mar 2021 |
| FY2019 | 31 Dec 2019 | $111.8M | -$146.0M | -$84.5M | -$1.71 | -$60.4M | 10-K filed 2 Mar 2020 |
| FY2018 | 31 Dec 2018 | $29.9M | -$112.2M | -$126.8M | -$2.61 | -$104.3M | 10-K filed 1 Mar 2019 |
| FY2017 | 31 Dec 2017 | $64.8M | -$43.9M | -$53.5M | -$1.17 | -$36.6M | 10-K filed 1 Mar 2018 |
| FY2016 | 31 Dec 2016 | $41.6M | -$54.3M | -$66.7M | -$1.65 | -$51.6M | 10-K filed 16 Mar 2017 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $28.5M | $13.2M | $0.15 |
| Q1 FY2026 | 31 Mar 2026 | $9.9M | $56.1M | $0.62 |
| Q2 FY2025 | 30 Jun 2025 | $0 | -$25.4M | -$0.43 |
| Q1 FY2025 | 31 Mar 2025 | $0 | -$33.5M | -$0.58 |
| Q3 FY2021 | 30 Sep 2021 | $30.0M | -$22.7M | -$0.36 |
| Q2 FY2021 | 30 Jun 2021 | $28.8M | -$28.6M | -$0.46 |
| Q1 FY2021 | 31 Mar 2021 | $21.1M | -$35.1M | -$0.57 |
| Q4 FY2020 | 31 Dec 2020 | $10.6M | -$37.3M | -$0.60 |
Company events
The newest 8-K filings of 180 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 13 Aug 2026 | 8-K | Leadership change | 5.02 |
| 12 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 20 Jul 2026 | 8-K | Other events | 8.01 |
| 6 Jul 2026 | 8-K | Other events | 8.01 |
| 25 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 18 Jun 2026 | 8-K | Other events | 8.01 |
| 13 May 2026 | 8-K | Results | 2.02, 9.01 |
| 31 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 7 Jan 2026 | 8-K | Results | 2.02 |
| 29 Dec 2025 | 8-K | Other events | 8.01, 9.01 |
| 1 Dec 2025 | 8-K | Deal completed, Agreement ended, Other events | 1.02, 2.01, 8.01, 9.01 |
| 13 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 390 held.
| Filed | Form | Period |
|---|---|---|
| 13 Aug 2026 | S-8 | – |
| 13 Aug 2026 | 8-K | 12 Aug 2026 |
| 12 Aug 2026 | 10-Q | 30 Jun 2026 |
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 20 Jul 2026 | 8-K | 20 Jul 2026 |
| 6 Jul 2026 | 8-K | 2 Jul 2026 |
| 25 Jun 2026 | 8-K | 18 Jun 2026 |
| 18 Jun 2026 | 8-K | 17 Jun 2026 |
| 13 May 2026 | 10-Q | 31 Mar 2026 |
| 13 May 2026 | 8-K | 13 May 2026 |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 30 Apr 2026 | DEF 14A | 18 Jun 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 23 Sep 2026 | Borges David J., VP, Finance & CAO | Sale under a trading plan | 10,000 | $20.95 | $209.5K | 0 | 24 Sep 2026 |
| 22 Sep 2026 | Borges David J., VP, Finance & CAO | Sale under a trading plan | 10,000 | $20.95 | $209.5K | 0 | 24 Sep 2026 |
| 31 Aug 2026 | Cancelmo Peter B, VP, General Counsel | Sale outside a trading plan | 25,000 | $18.54 | $463.5K | 200 | 1 Sep 2026 |
| 28 Aug 2026 | Cancelmo Peter B, VP, General Counsel | Sale outside a trading plan | 25,000 | $18.65 | $466.1K | 200 | 1 Sep 2026 |
| 27 Aug 2026 | Hanish Arnold C, Director | Sale outside a trading plan | 5,000 | $18.88 | $94.4K | 5,000 | 28 Aug 2026 |
| 27 Aug 2026 | Hanish Arnold C, Director | Sale outside a trading plan | 5,000 | $19.02 | $95.1K | 0 | 28 Aug 2026 |
| 26 Aug 2026 | Hanish Arnold C, Director | Sale outside a trading plan | 5,000 | $18.53 | $92.6K | 0 | 28 Aug 2026 |
| 24 Aug 2026 | Borges David J., VP, Finance & CAO | Sale under a trading plan | 906 | $19.10 | $17.3K | 0 | 25 Aug 2026 |
| 21 Aug 2026 | Borges David J., VP, Finance & CAO | Sale under a trading plan | 10,000 | $18.95 | $189.5K | 0 | 25 Aug 2026 |
| 20 Aug 2026 | Cable Thomas J., Director | Sale outside a trading plan | 15,000 | $18.45 | $276.8K | 35,067 | 21 Aug 2026 |
| 13 Aug 2026 | Borges David J., VP, Finance & CAO | Sale under a trading plan | 5,000 | $16.95 | $84.8K | 0 | 17 Aug 2026 |
| 22 May 2026 | Cable Thomas J., Director | Sale under a trading plan | 7,500 | $11.61 | $87.0K | 35,067 | 27 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 23 Sep 2026 | DAVID BORGES, Officer | 14,927 | $314.2K | 23 Sep 2026 |
| 22 Sep 2026 | DAVID BORGES, Officer | 10,000 | $184.9K | 22 Sep 2026 |
| 31 Aug 2026 | PETER CANCELMO, Officer | 25,000 | $463.5K | 31 Aug 2026 |
| 28 Aug 2026 | PETER CANCELMO, Officer | 25,000 | $466.1K | 28 Aug 2026 |
| 27 Aug 2026 | ARNOLD HANISH, Director | 10,000 | $189.5K | 27 Aug 2026 |
| 26 Aug 2026 | ARNOLD HANISH, Director | 5,000 | $94.1K | 26 Aug 2026 |
| 21 Aug 2026 | DAVID BORGES, Officer | 10,906 | $203.2K | 21 Aug 2026 |
| 20 Aug 2026 | THOMAS CABLE, Director | 15,000 | $276.8K | 20 Aug 2026 |
| 13 Aug 2026 | DAVID BORGES, Officer | 5,000 | $68.5K | 13 Aug 2026 |
| 22 May 2026 | Thomas Cable, Director | 7,500 | $89.7K | 22 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 29 Jul 2026 | BlackRock, Inc. | 13G amended | 8.2% | 6.0M |
| 23 Apr 2026 | INGALLS & SNYDER LLC | 13G amended | 4.8% | 3.5M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 30 Jan 2026 | The Vanguard Group | 13G | 5.66% | 4.0M |
| 31 Oct 2025 | The Vanguard Group | 13G amended | 4.91% | 3.3M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 11.4M | +0.41% | 12.17 |
| 30 Sep 2026 | 11.4M | -8.88% | 6.95 |
| 15 Sep 2026 | 12.5M | -2.09% | 9.31 |
| 31 Aug 2026 | 12.8M | -12.85% | 7.3 |
| 14 Aug 2026 | 14.6M | -5.07% | 4.91 |
| 31 Jul 2026 | 15.4M | +2.18% | 9.87 |
| 15 Jul 2026 | 15.1M | -0.29% | 11.85 |
| 30 Jun 2026 | 15.1M | -16.39% | 5.61 |
Funds that hold it
From each fund's latest Form 13F.
196 funds held it at 30 Jun 2026: 96 added and 39 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 6,044,633 | $57.5M | +735,007 |
| Ingalls & Snyder LLC | 3,659,523 | $34.8M | +100,100 |
| UBS Group AG | 3,148,384 | $29.9M | +807,653 |
| Vanguard Capital Management LLC | 3,072,050 | $29.2M | +88,791 |
| State Street Corp. | 2,319,906 | $22.1M | +400,331 |
| Geode Capital Management, LLC | 1,914,460 | $18.2M | +162,137 |
| Stifel Financial Corp. | 1,836,925 | $17.5M | +5,340 |
| Vanguard Portfolio Management LLC | 962,828 | $9.2M | +244,153 |
| Invesco Ltd. | 751,771 | $7.1M | +571,142 |
| Northern Trust Corp. | 727,348 | $6.9M | +163,481 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B